Exploring MMP14 as a Prognostic and Immune Biomarker in Lung Cancer

• by Jiajia Xiao, Zhenpeng Zhu, Fan Zhang, Xinsheng Wang

• January 17, 2026

ZNF25 as an immunotherapy target: pan-cancer biomarker potential and mechanistic exploration in glioma

• by Xiaohong Yi, Xianwen Zhang, Lijun Huang, Yuhui Chen, Maochun You, Hongyi Jia, Lefeng Hou, Chao Hu, Kun Huang, Yumei Wang

• June 2, 2026

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

• by

• June 1, 2026

• 5 min

Risk prediction models for postoperative atrial fibrillation in patients with lung cancer: a systematic review and meta-analysis

• by Fei Yang, Tenglu Sun, Yi Shang, Yuanyuan Chen, Jinxiang Wu, Xuli Shang

• June 2, 2026